Microarrays are keychain-sized devices with as many as several million tiny spots, each of which examines genes of interest simultaneously using minute sample volumes. This highly sensitive technology is relatively new, and standard procedures to ensure the reliability and comparability of results are only beginning to emerge. For instance, results can change as a result of differences in how tissues are collected and processed; variations in how the molecules are counted, attached to substrates and labeled for detection; deviations from recommended protocols by lab personnel; and malfunctioning or miscalibrated equipment. Such variations need to be controlled before this technology can be used reliably in clinical settings and in devices requiring regulatory approval, according to the paper.
As a first step toward addressing reliability issues, a consortium co-led by NIST and industry is developing standards that will satisfy needs identified at a 2003 workshop. At the workshop, organized and hosted by NIST, leaders in the microarray field from industry, government and universities recommended the development of a well-characterized set of ribonucleic acid (RNA) molecules whose identity and concentration are known. RNA is an important product of gene activity. Users will be able to validate the results of gene chip analyses by adding such a reference material to their samples and comparing the measured values to what would be expected for them. Such a reference material also will enable technology developers and researchers to assess the performance of their assays.
The paper was co-authored by scientists from Genomic Health, Inc., Agilent Technologies, the U.S. Food and Drug Administration, and The Institute for Genome Research.